Martingale Asset Management L P Kinnate Biopharma Inc. Transaction History

Martingale Asset Management L P

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 12, 2023	SELL	$3.46 - $7.98 $2,422 - $5,586	-700 Reduced 3.11%	21,822 $136,000
Q4 2022 Feb 13, 2023	BUY	$5.26 - $12.19 $118,465 - $274,543	22,522 New	22,522 $137,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.